Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary rocuronium concentration during hepatic blood flow interruption in hepatectomy
jRCT1031230635Recruiting
- Sponsor
- MSD
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rocuronium in hepatic neoplasm, sponsored by MSD. Primary endpoint: Urinary rocuronium concentration before and after hepatic blood flow blockade. Started Feb 2024; status: recruiting.
02
Drugs
rocuronium
03
Conditions
hepatic neoplasm
Beyond the preview
Go deeper on jRCT1031230635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230635.